Repurposing of androgen receptors inhibitors for prostate cancer treatment to treat other cancer in males such as melanoma.
Diagnostic software to stratify patients on biomarkers and therapeutic targets.
Inhibition of cyclin-dependent-kinase 7 (CDK7) for treatment of refractory castration-resistant prostate cancer (CRPC) through reduction of androgen receptor transcriptional activity.